Letter From The Editor

Recently the AHA and ACC tightened up their guidelines for better control. These controls are especially important for diabetes patients. This week, one of our favorite presenters, Dr. Claude Lardinois, M.D., FACP, FACE, MACN, who was recently elected as a Fellow of the American College of Endocrinology, starts a series of Homerun …

I recently converted one of my aero road bikes from a 22-speed to a single speed, which means I only have one gear. I can still get up to 27 mph on a sprint, but instead of pedaling at 80 revolutions a minute, I am forced to pedal at 123 …

The SGLT-2 inhibitors continue to garner headlines and scientific publications as our knowledge of how they work and what they can do increases. Part of the reason all this is happening at a rapid pace is the multiple brands available on the class. This means that endpoint studies can be …

The pressures of reimbursement have taken their affect on the amount of time that a patient gets to spend with their clinician. This means that often there is no time for you to say everything to your patient that you would like to and that means that the obesity conversation …

Many years ago, when Steve and I were first sending our newsletter to a few pharmacists, we realized we needed to offer more than any other diabetes newsletter. We were the new kids on the block; we weren’t journalists, but we were pharmacists. So we started to look for well-respected, …

For the past three years, I have been working with a Pharma company to build a network of independent pharmacies for prescribers to send their patients to. When we started this, the idea was simple — “send your patients to someone you would want to go to.” In the last …

Every week we bring you great information on the latest details of new drugs and new studies on old drugs. In fact in 2018 alone we have had over 20 articles on pharmaceuticals. This plethora of choices and information often overwhelms even the most astute clinician, and when you add …

There have been a lot of diseases associated with diabetes, and it is often said that, although it is never on the death certificate, diabetes is the biggest killer. We often can think of some of the common ones, like heart failure, stroke, and kidney failure. And other conditions that …

When I was working with endocrinologists they would often place their type one patients on metformin. I would share this with primary prescribers, and they too had good results using a type 2 drug for insulin dependent patients. We now have more choices than ever for patients and it only …

There seems to be a consensus amongst medical professionals and researchers that patients don’t want to test their glucose regardless of how bad their condition is. It appears that CGMS is the future according to a lot of experts. But is it feasible in the real world? This week, we …